Jennifer Jarrett bought $253K of Damora Therapeutics (DMRA)
Executed Sep 25, disclosed Sep 28, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 28), the stock returned +0.0% (delay-adjusted); from the execution session (Sep 25), +1.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Jennifer Jarrett (Director, President and CEO) filed 3 Form 4 reports in the trailing twelve months (1 purchase, 2 sales), most often in Arcus Biosciences, Inc. (RCUS). Across 1 priced purchase filing, the average 21-session return was +1.4% from execution and +0.0% from disclosure (delay-adjusted; derived). The largest single filing was $467K of RCUS (21,208 sh across 2 lots, as filed), executed Dec 16 2025.
Healthcare · Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→